---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-049060"
form_type: "8-K"
ticker: "IOVA"
cik: "0001425205"
company_name: "IOVANCE BIOTHERAPEUTICS, INC."
filed_at: "2023-04-24T23:59:59+00:00"
generated_at: "2026-06-16T18:44:49.647545+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.25
calibrated_materiality_score: 0.25
confidence: "high"
source: SEC EDGAR
---

# Iovance appoints Wendy L. Yarno to Board; Wendy L. Dixon not standing for re-election

## Summary
- Wendy L. Yarno appointed as director effective April 18, 2023; previously EVP & CMO at Merck over 26 years.
- Wendy L. Dixon will not stand for re-election at June 2023 annual meeting; will serve until meeting ends.
- Board increased from 7 to 8 members for Yarno's seat; will reduce back to 7 after annual meeting.
- Yarno granted standard deferred restricted stock unit per new-director compensation; no related-party transactions.

## SEC filing metadata
- accession: 0001104659-23-049060
- form_type: 8-K
- ticker: IOVA
- cik: 0001425205
- company_name: IOVANCE BIOTHERAPEUTICS, INC.
- filed_at: 2023-04-24T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.25
- calibrated_materiality_score: 0.25
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1425205/000110465923049060/0001104659-23-049060-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1425205/000110465923049060/tm2313552d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-049060
- JSON: https://secwatch.observer/filing/0001104659-23-049060.json
- Plain text: https://secwatch.observer/filing/0001104659-23-049060.txt

## Key facts
- Executive change
  Wendy L. Dixon departed as director at IOVANCE BIOTHERAPEUTICS, INC..
  - Action: will not be standing for re-election
  - Role: director
  source text: Wendy L. Dixon, a member of the Board, will not be standing for re-election to the Board at the Company’s annual meeting of stockholders currently anticipated to be held in June 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1425205/000110465923049060/0001104659-23-049060-index.htm
- Executive change
  Wendy L. Yarno was appointed as director at IOVANCE BIOTHERAPEUTICS, INC..
  - Action: appointed
  - Role: director
  source text: appointed Wendy L. Yarno as a director and new member of the Board, effective April 18, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1425205/000110465923049060/0001104659-23-049060-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.